Lucid Posts $1.2M Q3 Revenue as Medicare Starts Paying for EsoGuard
LUCD sits 39% above its 52-week low of $0.303 on light trading volume (0.3× avg).
Summary
Lucid reported $1.2 million of Q3 revenue and a $6.7 million net loss, with Medicare now paying EsoGuard claims at $1,938.01 per test and October test volume hitting a record above 1,800.
Key Events · Earnings and Guidance · LUCD
-
Medicare Now Paying EsoGuard Claims
Lucid received its first Medicare payments in October at the established Clinical Laboratory Fee Schedule rate of $1,938.01 per test, independent of the pending MolDX LCD reconsideration.
-
Q3 Revenue $1.2M, Loss $6.7M
Third quarter revenue was $1.2 million on 2,871 EsoGuard tests; operating expenses were $13.5 million and GAAP net loss was $6.7 million, or $(0.03) per share.
-
October Volume Sets Record
More than 1,800 EsoGuard tests were performed in October, a record month and already above the 2,871 tests done across the whole third quarter.
-
Cash Falls to $18.0M
Cash and equivalents were $18.0 million at September 30, 2026, versus $34.7 million at December 31, 2025; the $15.0 million Series C preferred financing closed after quarter-end.
Analysis · LUCD · Industrial Applications And Services
The quarter itself was small — $1.2 million of revenue against $13.5 million of operating expenses — but the reimbursement shift is the real story. Medicare is now paying claims at the established $1,938.01 per-test rate, turning EsoGuard from a test with no payer into one with a real revenue channel. October volume of more than 1,800 tests already exceeds the 2,871 done in the entire third quarter, so the fourth quarter is the first real read on whether that channel converts into revenue. Against that, cash fell to $18.0 million from $34.7 million at year-end, and the $15.0 million preferred financing closed after quarter-end — runway remains the binding constraint, and the stock is under a Nasdaq bid-price notice disclosed October 16.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LUCD was trading at $0.42 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $77.5M. The 52-week trading range was $0.30 to $1.63. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.